Novo Nordisk A/S (NYSE:NVO)
| 58.13 Delayed Data As of 6:30pm ET |  -1.36 / -2.29%Today’s Change | 46.47 Today|||52-Week Range 64.82 | +0.43% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $115.9B |
Company Description
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Contact Information
Novo Nordisk A/S Novo Allé Bagsværd Capital Region 2880 |
Employees
Shareholders
| Other institutional | 7.43% |
| Mutual fund holders | 1.78% |
| Individual stakeholders | -- |
Top Executives
| There are no executives to display. |
